MX2016002302A - Composiciones y metodos terapeuticos para la regresion acelerada de placa. - Google Patents

Composiciones y metodos terapeuticos para la regresion acelerada de placa.

Info

Publication number
MX2016002302A
MX2016002302A MX2016002302A MX2016002302A MX2016002302A MX 2016002302 A MX2016002302 A MX 2016002302A MX 2016002302 A MX2016002302 A MX 2016002302A MX 2016002302 A MX2016002302 A MX 2016002302A MX 2016002302 A MX2016002302 A MX 2016002302A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salt
compositions
therapeutic methods
therapeutically effective
Prior art date
Application number
MX2016002302A
Other languages
English (en)
Inventor
Kenneth Eugene Lebioda
Jan Ove Johansson
F Allan Gordon
Fabrizio Simone Chiacchia
Christopher Ross Armstrong Halliday
Ewelina B Kulikowski
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of MX2016002302A publication Critical patent/MX2016002302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención comprende métodos para tratar y/o prevenir trastornos cardiovasculares, relacionados con colesterol y lípidos, inclusive la aterosclerosis, mediante la coadministración de cantidades terapéuticamente eficaces de RVX-208 o una sal farmacéuticamente aceptable de esta y rosuvastatina o una sal farmacéuticamente aceptable de esta. La invención proporciona además composiciones que comprenden una cantidad terapéuticamente eficaz de RVX-208 o una sal farmacéuticamente aceptable de esta y una cantidad terapéuticamente eficaz de rosuvastatina o una sal farmacéuticamente aceptable de esta.
MX2016002302A 2013-08-21 2014-08-21 Composiciones y metodos terapeuticos para la regresion acelerada de placa. MX2016002302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361868386P 2013-08-21 2013-08-21
PCT/IB2014/002546 WO2015025226A2 (en) 2013-08-21 2014-08-21 Compositions and therapeutic methods for accelerated plaque regression

Publications (1)

Publication Number Publication Date
MX2016002302A true MX2016002302A (es) 2016-06-15

Family

ID=52484226

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002302A MX2016002302A (es) 2013-08-21 2014-08-21 Composiciones y metodos terapeuticos para la regresion acelerada de placa.

Country Status (14)

Country Link
US (1) US20160206617A1 (es)
EP (1) EP3035934A4 (es)
JP (1) JP2016528275A (es)
KR (1) KR20160043117A (es)
CN (1) CN105473144A (es)
AU (1) AU2014310369A1 (es)
BR (1) BR112016003584A8 (es)
CA (1) CA2921985A1 (es)
CL (1) CL2016000379A1 (es)
EA (1) EA201690284A1 (es)
HK (1) HK1219434A1 (es)
IL (1) IL244166A0 (es)
MX (1) MX2016002302A (es)
WO (1) WO2015025226A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
MX2021012876A (es) 2009-03-18 2022-06-23 Resverlogix Corp Nuevos agentes anti-inflamatorios.
ES2821018T3 (es) 2009-04-22 2021-04-23 Resverlogix Corp Nuevos agentes antiinflamatorios
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
KR20160043118A (ko) * 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
MX2022005029A (es) * 2019-11-05 2022-07-12 Resverlogix Corp Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.
KR20220124736A (ko) * 2020-01-08 2022-09-14 리스버로직스 코퍼레이션 Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556545A (en) * 2002-03-22 2009-03-31 Novartis Ag Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
CN101641339B (zh) * 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
EP2675445A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
AU2014205553A1 (en) * 2013-01-08 2015-07-09 Volant Holdings Gmbh Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems
KR20160043118A (ko) * 2013-08-21 2016-04-20 리스버로직스 코퍼레이션 가속화된 경화반 퇴행을 위한 조성물 및 치료방법

Also Published As

Publication number Publication date
EA201690284A1 (ru) 2016-08-31
HK1219434A1 (zh) 2017-04-07
EP3035934A4 (en) 2017-04-26
BR112016003584A8 (pt) 2018-01-30
CN105473144A (zh) 2016-04-06
KR20160043117A (ko) 2016-04-20
WO2015025226A2 (en) 2015-02-26
CA2921985A1 (en) 2015-02-26
US20160206617A1 (en) 2016-07-21
WO2015025226A9 (en) 2015-12-03
EP3035934A2 (en) 2016-06-29
IL244166A0 (en) 2016-04-21
CL2016000379A1 (es) 2016-08-26
AU2014310369A1 (en) 2016-03-10
JP2016528275A (ja) 2016-09-15
AU2014310369A2 (en) 2016-04-21
WO2015025226A3 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
MX2016002178A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
MX2016002302A (es) Composiciones y metodos terapeuticos para la regresion acelerada de placa.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
PH12016500024A1 (en) Bromodomain inhibitor
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
AU2024202106A1 (en) Fixed dose combinations and formulations comprising ETC1002 and Ezetimibe and methods of treating or reducing the risk of cardiovascular disease
IN2014DN10670A (es)
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
IL229424A0 (en) Pharmaceutical preparations containing neuropilin inhibitors and their uses in the prevention and/or treatment of angiogenic disorders and cancer
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
PH12020500472A1 (en) Autotaxin inhibitor compounds
GB201114923D0 (en) Immunogenic proteins and compositions
IN2013MU03429A (es)